BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8334429)

  • 21. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
    Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of recombinant human granulocyte macrophage colony-stimulating factor in autologous bone marrow transplantation.
    Nemunaitis JJ; Singer JW; Sanders JE
    Bone Marrow Transplant; 1991; 7 Suppl 3():24-7. PubMed ID: 1855082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
    Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
    Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential clinical applications of rhGM-CSF in acute myeloid leukemia based on its biologic activity and receptor interaction.
    Lanza F; Rigolin GM; Castagnari B; Moretti S; Castoldi G
    Haematologica; 1997; 82(2):239-45. PubMed ID: 9175331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation.
    Pene R; Appelbaum FR; Fisher L; Lilleby K; Nemunaitis J; Storb R; Buckner CD
    Bone Marrow Transplant; 1993 Mar; 11(3):219-22. PubMed ID: 8467286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood.
    Mills KC; Gross TG; Varney ML; Heimann DG; Reed EC; Kessinger A; Talmadge JE
    Bone Marrow Transplant; 1996 Jul; 18(1):53-61. PubMed ID: 8831996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
    Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
    Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients.
    Messina C; Zambello R; Rossetti F; Gazzola MV; Varotto S; Destro R; Basso G; Semenzato G; Zanesco L
    Bone Marrow Transplant; 1996 May; 17(5):729-35. PubMed ID: 8733689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.
    Triozzi PL; Tucker F; Benzies T; Balcerzak SP
    Bone Marrow Transplant; 1996 Jul; 18(1):47-52. PubMed ID: 8831995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A clinical study of rhG-CSF in accelerating hematological recovery following autologous hematopoietic stem cells transplantation].
    Yang JL; Shi YK; He XH; Zhou SY; Zhou AP; Han XH; Liu P; Zhang CG; Ai B
    Ai Zheng; 2003 Aug; 22(8):785-9. PubMed ID: 12917020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores decreased monocyte HLA-DR expression after cardiopulmonary bypass.
    Börgermann J; Friedrich I; Scheubel R; Kuss O; Lendemans S; Silber RE; Kreuzfelder E; Flohé S
    Thorac Cardiovasc Surg; 2007 Feb; 55(1):24-31. PubMed ID: 17285470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
    Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.
    Nemunaitis J; Rabinowe SN; Singer JW; Bierman PJ; Vose JM; Freedman AS; Onetto N; Gillis S; Oette D; Gold M
    N Engl J Med; 1991 Jun; 324(25):1773-8. PubMed ID: 1903847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mobilization of peripheral blood progenitor cells by cyclophosphamide and rhGM-CSF in multiple myeloma.
    Martínez E; Sureda A; Dalmases CD; Sánchez JA; Amill B; Tugues D; Sardá P; Miralles A; Brunet S; Domingo-Albós A; García J
    Bone Marrow Transplant; 1996 Jul; 18(1):1-7. PubMed ID: 8831988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of recombinant GM-CSF following allogeneic BMTs for aplastic anemia.
    Chap L; Schiller G; Nimer SD
    Bone Marrow Transplant; 1993 Aug; 12(2):173-5. PubMed ID: 8401368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human granulocyte-macrophage colony-stimulating factor (CSF), but not recombinant human granulocyte CSF, down-regulates the recombinant human stem cell factor-dependent differentiation of human fetal liver-derived mast cells.
    Du Z; Li Y; Xia H; Irani AM; Schwartz LB
    J Immunol; 1997 Jul; 159(2):838-45. PubMed ID: 9218602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.